N-Methyl-2C-B
N-Methyl-2C-B, or N-Me-2C-B, also known as 2C-B-M or 2C-BM, as well as 4-bromo-2,5-dimethoxy-N-methylphenethylamine, is a serotonin receptor modulator of the phenethylamine and 2C families. It is the N-methyl derivative of 2C-B.
N-Methyl-2C-B has been tested in humans by P. Rausch and was reported to be completely inactive.
Pharmacology
Pharmacodynamics
N-Methyl-2C-B showed affinity for the serotonin 5-HT2 receptors, specifically for the serotonin 5-HT2A and 5-HT2C receptors. Its affinities were 2.9nM for the DOI-labeled serotonin 5-HT2A receptor, 380nM for the ketanserin-labeled serotonin 5-HT2A receptor, and 100nM for the serotonin 5-HT2C receptor. These affinities were approximately 3-fold, 11-fold, and 3-fold lower than those of 2C-B, respectively.
History
N-Methyl-2C-B was first described in the scientific literature by Richard Glennon and colleagues by 1994. It was encountered as a novel designer drug in Europe in 2014.
Canada
N-Methyl-2C-B is a controlled substance in Canada under phenethylamine blanket-ban language.